At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
Cefdinir Capsules 300 mg +1 moredrug
Likely dose
Cefdinir Capsules 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Relative Bioavailability Study of 300 mg Cefdinir Capsules Under Fasting Conditions
In Brief
A Phase 1 clinical trial evaluating Cefdinir Capsules 300 mg and OMNICEF® 300 mg for Healthy. Completed, enrolled 32 participants across 2 sites.
Detailed Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 300 mg Cefdinir Capsules manufactured and distributed by TEVA pharmaceuticals USA with that of OMNICEF® Capsules by CEPH International Corporation for Abbott Laboratories following a single oral dose (1 x 300mg capsule) in healthy adult subjects administered under fasting conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2005
Primary CompletionJul 2005
First PostedFeb 2009
TodayJul 2026
First PostedFeb 3, 2009
Enrollment StartJul 1, 2005
Primary CompletionJul 1, 2005
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.4 years ago
Interventions
Cefdinir Capsules 300 mgdrug
1 x 300 mg, single-dose fasting
OMNICEF® 300 mgdrug
1 x 300 mg, single-dose fasting